BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 29616044)

  • 1. Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
    McLaughlin LP; Bollard CM; Keller MD
    Front Immunol; 2018; 9():556. PubMed ID: 29616044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
    Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
    J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
    Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
    J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr Virus
    Magg T; Schober T; Walz C; Ley-Zaporozhan J; Facchetti F; Klein C; Hauck F
    Front Immunol; 2018; 9():368. PubMed ID: 29535735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J; Bornkamm GW
    Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells for viral infections after allogeneic hematopoietic stem cell transplant.
    Bollard CM; Heslop HE
    Blood; 2016 Jun; 127(26):3331-40. PubMed ID: 27207801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
    Zhou L; Lu DP
    Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant.
    Comoli P; Basso S; Labirio M; Baldanti F; Maccario R; Locatelli F
    Blood Cells Mol Dis; 2008; 40(1):68-70. PubMed ID: 17904879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders.
    McLaughlin LP; Bollard CM; Keller M
    Curr Allergy Asthma Rep; 2017 Jan; 17(1):3. PubMed ID: 28116637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid generation of Epstein-Barr virus-specific T cells for cellular therapy.
    Hao QF; Yang YX; Wang Y; Chen LM; Sheng GY; Luan Z
    Transplant Proc; 2014; 46(1):21-5. PubMed ID: 24507020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
    Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
    Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive T-Cell Immunotherapy.
    Gottschalk S; Rooney CM
    Curr Top Microbiol Immunol; 2015; 391():427-54. PubMed ID: 26428384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.